Hub-building MD Anderson partners with Theraclone on $9.5M biotech startup

Seattle-based Theraclone is launching a new biotech focused on the burgeoning field of cancer immunotherapies–OncoResponse–that will operate in Houston in partnership with the entrepreneurial researchers at MD Anderson, setting out with a $9.5 million Series A.

Source: www.fiercebiotech.com

---